To offer you a better experience, our website uses some cookies. To continue the visit, please accept our cookie policy

I agree

Cookies information

Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:

Statistics

We use tools, such as Google Analytics, to track web traffic and verify the effectiveness of our site.

Necessary

Cookies required for essential services and features such as login forms, shopping cart integration and access control. Without them, our website cannot function properly and we cannot provide any services. Deactivation is not available.

These settings will be kept for 24h

About us

Bioxodes is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics to prevent thrombotic events without hemorrhagic risk.

Company Overview

About us

Company overview

Bioxodes takes advantage of its deep understanding of thrombotic processes to design novel product candidates with an aim to achieve anticoagulation without hemorrhagic risk.

Our innovative pipeline includes a clinical-stage program for the prevention of acute thrombo-inflammatory processes.

The lead product candidate of this program, Ir-CPI, exhibits a unique mechanism of action by targeting coagulation factors (FXIIa and FXIa) and neutrophils, key driver components of thrombo-inflammatory processes involved in various diseases such as stroke, rheumatoid arthritis, lupus and sepsis.

Bioxodes has recently completed with success the active phase of its First-in-Human study performed in healthy adult volunteers with Ir-CPI.

In parallel, Bioxodes is developing a pipeline of drug candidates targeting chronic thrombo-inflammatory and inflammatory diseases.

Bioxodes is located in the Brussels South Charleroi Biopark, Belgium.

Our Team

Management

    • Godfroid Edmond

      Before founding Bioxodes, Edmond Godfroid was a long standing senior Professor at the University of Brussels (ULB) where he applied his expertise in molecular biology to the discovery of pharmacologically active proteins in the saliva of the tick Ixodes ricinus. Dr Godfroid’s and his former team’s work is the basis for the creation of Bioxodes. He received his PhD in Molecular Biology from the ULB in 1988 and subsequently acquired post-doctoral experience in the field of Alzheimer’s disease at the Université Catholique de Louvain (UCL). In 1992, he joined Applied Genetics (ULB) where he developed the first PCR-based diagnostic device specific to the tick-borne bacterial pathogen, Borrelia burgdorferi, the causal agent of Lyme disease. In 1995, Dr Godfroid began researches on the molecular interaction between Ixodes ticks and their hosts. He was the Head of the Ectoparasite Molecular Biology Unit at ULB. He has experience of a range of collaborations with academic groups and pharmaceutical companies. Dr Godfroid is a co-founder of Bioxodes.

    • Detrixhe Pierre

      Pierre Detrixhe is Managing Partner at Financière spin-off luxembourgeoise and Venture Director at Newton Biocapital. He brings more than 10 years of experience in the field of venture capital and has accompanied many companies in the start-up phase. Previously, he held positions of scientist and technology transfer officer in the biotechnology field. Pierre Detrixhe is Director at the Board of some promising Belgian start-up companies. He holds a Master in Bioengineering from the University of Liège (Gembloux Agro-Bio Tech), Belgium and a Master in Management from the Catholic University of Louvain, Belgium.

    • Fontaine François

      François Fontaine holds a law degree from the University of Brussels and he is a specialist in Tax affairs. He was counsel in various public institutions and cabinet. He is currently general counsel to the Federal Holding and Investment Company (SFPI)-FPIM. SFPI is focusing its investments on innovative Belgian Companies, hoping to contribute to their financial and societal success story. Mr. Fontaine is also a Board member of several companies including biotechs.

    • Croughs Thérèse

      Dr Thérèse Croughs has over 30 years of experience in the Pharma and Biotech Industry, specializing in the provision of clinical development and regulatory strategy services to manufacturers and developers of biologics and biotech products. She brings a high level of medical expertise in the fields of hematology, immunology, infectious diseases and oncology, as well as experience of clinical development in biotechnology and regulatory affairs, having taken a number of early stage compounds from preclinical studies to the clinic. Dr Croughs started her career working in R&D for Bayer, NovoNordisk and BioAlliance Pharma, Paris, before joining Cytheris and then Neovacs as CMO. Whilst there, she was responsible for all R&D development activities, including Regulatory Affairs in EU, US as well as ROW. This included the registration of Kogenate® in EU, Loramyc® (miconazole Lauriad) in FR-EU and US/Japan, together with other applications using the same drug delivery technology. She was also responsible for the management of Medical Affairs and R&D and the development of a NCE pipeline (therapies developed to target drug resistance such as small molecules in infectious diseases, gene therapy in oncology).

    • Godfroid Edmond

      Before founding Bioxodes, Edmond Godfroid was a long standing senior Professor at the University of Brussels (ULB) where he applied his expertise in molecular biology to the discovery of pharmacologically active proteins in the saliva of the tick Ixodes ricinus. Dr Godfroid’s and his former team’s work is the basis for the creation of Bioxodes. He received his PhD in Molecular Biology from the ULB in 1988 and subsequently acquired post-doctoral experience in the field of Alzheimer’s disease at the Université Catholique de Louvain (UCL). In 1992, he joined Applied Genetics (ULB) where he developed the first PCR-based diagnostic device specific to the tick-borne bacterial pathogen, Borrelia burgdorferi, the causal agent of Lyme disease. In 1995, Dr Godfroid began researches on the molecular interaction between Ixodes ticks and their hosts. He was the Head of the Ectoparasite Molecular Biology Unit at ULB. He has experience of a range of collaborations with academic groups and pharmaceutical companies. Dr Godfroid is a co-founder of Bioxodes.

    • Warrinnier Hans

      Dr. Hans Warrinnier joined Bioxodes following a leadership tenure at Roche Belgium where he held various senior leadership positions such as Medical Director. In this position, he led a team of 70+ across Clinical Operations, Medical Affairs and Medical Information, Drug Safety and Regulatory Affairs. He developed and supported affiliate and global clinical studies in different therapeutic areas, maintaining Belgium’s top spot in clinical trials per capita in the world. He delivered strategic expertise and advice for market access solutions in Belgium across different therapeutic areas, including oncology, hematology, neurology, immunology, and hemophilia. In addition to receiving his medical degree from the KU Leuven in Belgium, Dr. Warrinnier followed Business school programs from London Business School and Harvard Business School.

    • Tassignon Joël

      Joël Tassignon obtained his PhD in immunology from the University of Brussels (ULB) and a Master in Total Quality Management from the Polytechnic Faculty of the University of Mons. After postdoctoral research on breast cancers at Bordet Institute (Brussels) and on transplantation at Erasme Hospital (ULB, discovery of a new immunosuppressant), he became project manager and lab director of a ULB spin-off. He then continued working in the management field as coach in innovation for companies and as director of a laboratory in a Belgian research center acting as a CRO. In parallel to the management of people, projects, technological platforms and laboratories, he was also involved in the management of several types of quality systems as manager and auditor. Joël is now Senior Project Manager and Quality Assurance Manager at Bioxodes.

    • Derochette Sandrine

      Sandrine Derochette obtained her PhD in Biochemistry and Cellular and Molecular Biology from the University of Liège in 2015 (study of the effect of curcumin on oxidative response of neutrophils). After her PhD, she joined Bioxodes as Study Coordinator in 2015. She is now Project Manager and member of the Quality Assurance team at Bioxodes.

    • Pireaux Valérie

      Valérie Pireaux obtained her PhD in Biochemistry and Cellular and Molecular Biology (atherosclerosis specialization) from the University of Namur in 2017. After her PhD, she joined Bioxodes as Preclinical Scientist in 2017.

    • Hess Estelle

      Estelle Hess obtained her PhD in Immunology from the University of Strasbourg in 2011. She pursued her career by a postdoc at the University of Namur in the field of host pathogen interactions. In 2018, she joined a private company specialized in the development of diagnostic kits in the veterinary field as a project manager and then as an R&D manager. She joined Bioxodes in 2021 and is now holding a position of preclinical scientist.

    • Demoulin Stéphanie

      Stéphanie Demoulin obtained her PhD in Biomedical and Pharmaceutical Sciences (Immunology & cancer specialization) from the University of Liege in 2014 (study of the implication of dendritic cells in cervical cancer progression). After postdoctoral researches on therapeutic approaches for breast cancers at the University of Liège, she became Scientific Writer at Bioxodes in 2016. She is now leading medical writing activities at Bioxodes.

    • Corbisier Charlotte

      Charlotte obtained her Master in Pharmaceutical Sciences in 2014. Having started her career in pharmacies, she quickly reoriented herself in the field of clinical studies. She began her career in the field of Clinical Research Organization (Medpace) where she developed the qualities needed for the successful development of a Clinical Project Manager. She worked there for 2.5 years, before starting to work as a Clinical Project Manager for a large pharmaceutical company for 3 years (Bristol Myers Squibb). She joined Bioxodes in 2021 where she holds the position of Clinical Project Manager.

    • Hespel Cindy

      Cindy Hespel obtained her PhD in Immunology from the University of Brussels (ULB) in 2012 (Regulation of Adaptive Immune Responses by Conventional and Inflammatory Dendritic Cells). After her PhD, she began her career as Project Execution Manager (Global Medical Affairs Operations) at GlaxoSmithKline Vaccines for 2 years. She then moved to Bristol Myers Squibb as Clinical Trial-Global Submission Manager managing large portfolio across diverse Therapeutic Areas for 7 years before joining Bioxodes as Regulatory Affairs Manager in 2021.

About us

Scientific &
Clinical Advisory Board

  • Lecompte Thomas
  • Weitz Jeff
  • Pattou François
  • Hermans Cedric
  • Dubois Christophe
  • Vivien Denis
  • Marichal Thomas
    • Thomas Lecompte, M.D

      01.
      Geneva, Switzerland

      Dr. Lecompte is a former associate physician in the Hospital Department of Medicine and Full Professor in the Academic Department of Medicine at the University of Geneva. Since the beginning of his scientific carrier, Dr. Lecompte has been interested in haemostasis and more specifically in blood platelets. His first paper of basic research was on phospholipid metabolism in platelets and was published as a Letter in Nature. Dr. Lecompte has been since them interested in inherited platelet disorders – and the way to investigate them, including extracellular vesicles. Dr. Lecompte has conducted research on the so-called antiphospholipid antibodies and on acquired haemostatic disturbances in complex settings associated with a thrombotic risk (COVID-19; post-vaccine thrombosis and thrombocytopenia; haematological malignancies such as essential thrombocythemia and multiple myeloma; liver cirrhosis); on the phenotyping of primary haemostasis under flow conditions and of the blood coagulation system by means of thrombin generation assays; on the pharmacology of haemostasis (with special interest in laboratory testing for patients receiving antiplatelet agents and anticoagulant, including parenteral direct thrombin inhibitors; on transfusion products with haemostatic properties; and on heparin-induced thrombocytopenia).

    • Jeff Weitz, M.D

      02.
    • François Pattou, M.D

      03.
    • Cedric Hermans, M.D, Ph.D, FRCP (Lon, Edin)

      04.
    • Christophe Dubois, Ph.D

      05.
    • Denis Vivien, Ph.D

      06.
    • Thomas Marichal, Ph.D

      07.